Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 10.12.2019 Börsentäglich über 12.000 News von 620 internationalen Medien
Goldexplorer expandiert! Gebiete direkt neben 800 Mio. schwerem Nachbar erworben!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 571050 ISIN: DE0005710503 Ticker-Symbol: N/A 
1-Jahres-Chart
EMPRISE AG Chart 1 Jahr
5-Tage-Chart
EMPRISE AG 5-Tage-Chart

Aktuelle News zur EMPRISE

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.11.Lilly Announces Interim Analysis From EMPRISE Real-world Study765INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said that a new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty or EMPRISE real-world study...
► Artikel lesen
17.11.Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists557This analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1...
► Artikel lesen
28.03.Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 201965EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first...
► Artikel lesen
3 Nachrichten in den letzten 12 Monaten